Juliette Leon

Juliette Leon

Auto-generated profile, based on publicly available information

Juliette Leon

Department of Kidney and Metabolic Diseases Transplantation and Clinical Immunology, Necker Hospital, AP‐HP Paris France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
BLBaptiste Lamarthée
Baptiste Lamarthée
AMArmance Marchal
Armance Marchal
SCSoëli Charbonnier
Soëli Charbonnier
TBTifanie Blein
Tifanie Blein
JLJuliette Leon
Juliette Leon
JZJulien Zuber
Julien Zuber
The use of chimeric antigen receptor (CAR)-engineered regulatory T cells (Tregs) has emerged as a promising strategy to promote immune tolerance. However, in conventional T cells (Tconvs), CAR expression is often associated with tonic signaling, which can induce CAR-T cell dysfunction. The extent and effects of CAR tonic signaling vary greatly according to the expression intensity and intrinsic properties of the CAR. Here, we show that the 4-1BB CSD-associated tonic signal yields a more dramatic effect in CAR-Tregs than in CAR-Tconvs with respect to activation and proliferation. Compared to CD28 CAR-Tregs, 4-1BB CAR-Tregs exhibit decreased lineage stability and reduced in vivo suppressive capacities. Transient exposure of 4-1BB CAR-Tregs to a Treg stabilizing cocktail, including an mTOR inhibitor and vitamin C, during ex vivo expansion sharply improves their in vivo function and expansion after adoptive transfer. This study demonstrates that the negative effects of 4-1BB tonic signaling in Tregs can be mitigated by transient mTOR inhibition.

31 July 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
VPVictoria Poillerat
Victoria Poillerat
TGThomas Gentinetta
Thomas Gentinetta
JLJuliette Leon
Juliette Leon
AWAndreas Wassmer
Andreas Wassmer
MEMonika Edler
Monika Edler
LRLubka Roumenina
Lubka Roumenina
Hemopexin is the main plasmatic scavenger of cell-free heme, released in the context of intravascular hemolysis or major cell injury. Heme is indispensable for the oxygen transport by hemoglobin but when released outside of the erythrocytes it becomes a danger-associated molecular pattern, contributing to tissue injury. One of the mechanisms of pro-inflammatory action of heme is to activate the innate immune complement cascade. Therefore, we hypothesized that injection of hemopexin will prevent hemolysis-induced complement activation. Human plasma-derived hemopexin is compatible with the heme clearance machinery of the mice. 100 or 500 mg/kg of hemopexin was injected in C57Bl/6 mice before treatment with phenylhydrazine (inducer of erythrocytes lysis) or with PBS as a control. Blood was taken at different timepoints to determine the pharmacokinetic of injected hemopexin in presence and absence of hemolysis. Complement activation was determined in plasma, by the C3 cleavage (western blot) and in the kidneys (immunofluorescence). Kidney injury was evaluated by urea and creatinine in plasma and renal NGAL and HO-1 gene expression were measured. The pharmacokinetic properties of hemopexin (mass spectrometry) in the hemolytic mice were affected by the target-mediated drug disposition phenomenon due to the high affinity of binding of hemopexin to heme. Hemolysis induced complement overactivation and signs of mild renal dysfunction at 6 h, which were prevented by hemopexin, except for the NGAL upregulation. The heme-degrading capacity of the kidney, measured by the HO-1 expression, was not affected by the treatment. These results encourage further studies of hemopexin as a therapeutic agent in models of diseases with heme overload.

31 March 2023 in American Journal of Hematology
Verified
Journal Article
Open access
JLJuliette Leon
Juliette Leon
MLMarie‐Bénédicte LeStang
Marie‐Bénédicte LeStang
RSRebecca Sberro‐Soussan
Rebecca Sberro‐Soussan
ASAude Servais
Aude Servais
DADany Anglicheau
Dany Anglicheau
JZJulien Zuber
Julien Zuber
Overactivation of the complement alternative pathway drives the pathogenesis of primary atypical hemolytic uremic syndrome (aHUS). Genetically‐determined or acquired dysregulation of the complement is frequently identified in patients with aHUS, pregnancy‐related hemolytic uremic syndrome (HUS), and severe hypertension‐associated HUS. In contrast, it is still unclear whether self‐limited complement activation, which frequently occurs in other forms of HUS, provides key mechanistic clues or results from endothelial damage. Development of novel biomarkers is underway to firmly establish complement‐driven pathogenesis. C5 blockade therapy has revolutionized the management of aHUS patients, resulting in a halving of the subpopulation under chronic dialysis over the course of a few years. On the other hand, the efficacy of C5 blockade in secondary forms of HUS, as assessed by small and uncontrolled case series, is less compelling and should be investigated through properly designed prospective clinical trials. The increased risk of meningococcal infection, related to C5 inhibition, must be rigorously addressed with suitable prophylaxis. Treatment duration should be determined based on an individualized benefit/risk assessment.

17 February 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JZJulien Zuber
Julien Zuber
OBOlivia Boyer
Olivia Boyer
BNBénédicte Neven
Bénédicte Neven
IJIsabelle Jollet
Isabelle Jollet
VRVirginie Renac
Virginie Renac
RSRémi Salomon
Rémi Salomon
Acute graft‐versus‐host disease (GVHD) is a rare but frequently lethal complication after solid organ transplantation. GVHD occurs in unduly immunocompromised hosts but requires the escalation of immunosuppression, which does not discriminate between host and donor cells. In contrast, donor‐targeted therapy would ideally mitigate graft‐versus‐host reactivity while sparing recipient immune functions. We report two children with end‐stage renal disease and severe primary immune deficiency (Schimke syndrome) who developed severe steroid‐resistant acute GVHD along with full and sustained donor T cell chimerism after isolated kidney transplantation. Facing a therapeutic dead‐end, we used a novel strategy based on the adoptive transfer of anti‐HLA donor‐specific antibodies (DSAs) through the transfusion of highly selected plasma. After approval by the appropriate regulatory authority, an urgent nationwide search was launched among more than 3800 registered blood donors with known anti‐HLA sensitization. Adoptively transferred DSAs bound to and selectively depleted circulating donor T cells. The administration of DSA‐rich plasma was well tolerated and notably did not induce antibody‐mediated rejection of the renal allografts. Acute GVHD symptoms promptly resolved in one child. This report provides a proof‐of‐concept for a highly targeted novel therapeutic approach for solid organ transplantation‐associated GVHD.

3 April 2025 in The Journal of Pathology
Verified
Journal Article
Open access
LALéonie Albersammer
Léonie Albersammer
JLJuliette Leon
Juliette Leon
JMJelena Martinovic
Jelena Martinovic
JDJessy Dagobert
Jessy Dagobert
ELEmilie Lebraud
Emilie Lebraud
MRMarion Rabant
Marion Rabant
Chronic histiocytic intervillositis (CHI) is an inflammatory condition of the placenta, characterised by an abnormal, mainly macrophagic infiltrate within the intervillous space. Recent research suggests that CHI results from a ‘maternal‐foetal rejection’ mechanism, because at least some CHI cases fulfil the criteria for antibody‐mediated rejection (AMR) of kidney allografts according to the Banff classification [i.e. presence of anti‐human leukocyte antigen (HLA) paternal antibodies activating the complement or foetal‐specific antibodies (FSA), a macrophage‐rich infiltrate, and positive C4d immunostaining]. To gain further insights into CHI pathogenesis, we aimed to refine the phenotype of the inflammatory infiltrate using a multiplex immunofluorescence technique and to compare the mRNA signatures between CHI and AMR of kidney allografts. Twelve patients with C4d+ FSA+ CHI were included in the study and compared to a control group of 5 patients without inflammatory lesions on placental examination. We developed a multiplex immunofluorescence panel to identify CD4+ and CD8+ T lymphocytes, CD68+/CD206− and CD68+/CD206+ macrophages, and NK cells in the villi and intervillous space. Molecular signatures were studied using NanoString® technology and the B‐HOT panel recommended by the Banff classification for kidney allografts. Multiplex immunofluorescence revealed that the infiltrate in the intervillous space was mainly composed of CD68+/CD206− macrophages as well as a higher proportion of CD8+ lymphocytes in patients with CHI compared to controls. Densities of NK cells and CD4 T cells were very low. Molecular signatures showed an overexpression of HLA class II genes, an IFN‐γ signature, and cytokine gene sets in C4d+ FSA+ CHI patients, also involved in kidney AMR. These results reinforce the paradigm of maternal‐foetal rejection. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

4 October 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
JZJulien Zuber
Julien Zuber
JLJuliette Leon
Juliette Leon
JDJulie Déchanet-Merville
Julie Déchanet-Merville
HKHannah Kaminski
Hannah Kaminski
Belatacept, a fusion protein combining cytotoxic T-lymphocyte antigen-4 (CTLA-4) and the Fc region of human IgG1, is increasingly used as a calcineurin inhibitor-sparing regimen in patients with chronic graft dysfunction. Older kidney transplant recipients, particularly from expanded criteria donors, may be switched to belatacept due to poor renal recovery. However, late-onset cytomegalovirus (CMV) reactivation is increasingly reported with this treatment, especially in older patients with graft dysfunction. This suggests a progressive loss of CMV-specific T cell response, potentially driven by T cell exhaustion. Contributing factors include preexisting T cell dysfunction, increased viral antigen exposure, and interference in the PD-L1/PD-1 pathway by belatacept. mTOR inhibitors have shown efficacy in preventing CMV reactivation by reinvigorating CMV-specific T cells. These findings support combining belatacept with mTOR inhibitors in high-risk CMV-seropositive recipients and emphasize the need for personalized immune assessments to guide immunosuppressive strategies.